Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences is supported by a strengthening regulatory and commercial backdrop, as CMS’s updated TAVR coverage rules remove key barriers and should eventually expand procedure volumes for a platform that already showed 10.5% year-over-year ex-FX growth in Q2. Its Q2 results reinforced operating momentum, with revenue of $1,741 million, operating margin of 30.0%, and TMTT growth of 45.5% ex-FX, while TAVR remained the largest driver at $1,258 million and benefited from balanced U.S. and OUS demand. The company also has multiple growth catalysts in mitral and tricuspid therapies, a premium moat built on 15+ years of clinical data, and a long-term growth profile that can absorb tariff headwinds while still supporting annual operating margin expansion.

Edwards Lifesciences is exposed to meaningful execution and regulatory risk, and that can weigh on an otherwise strong structural-heart franchise. Its outlook is challenged by possible commercial hiccups, NCD and regulatory delays, product recalls, competition, and negative clinical data readouts, any of which could disrupt adoption across mitral, tricuspid, and heart-failure therapies. Although about 60% of sales come from outside the US and the pipeline is broad, the valuation already reflects a high bar, with a 30.5x 12-24 month adjusted EPS multiple at the high end of large-cap peers.